CHINA NATIONAL MEDICINES CORP (600511) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached ¥24.76 billion, up 2.55% year-over-year; net profit attributable to shareholders was ¥1.00 billion, up 1.62% year-over-year.

• Core pharmaceutical distribution business maintained stable growth amid industry reforms and policy changes.

• Company leveraged scale, network, and product diversity, with 100% coverage of Beijing's top hospitals and strong presence in retail and specialty drug markets.

• Industrial segment saw a year-over-year decline in revenue and profit due to market and policy shifts.

• No interim dividend or capital increase from reserves was proposed for the half-year.

Financial highlights

• Operating income: ¥24.76 billion, up 2.55% year-over-year.

• Net profit attributable to shareholders: ¥1.00 billion, up 1.62% year-over-year.

• Basic and diluted EPS: ¥1.3261, up 1.62% year-over-year.

• Net cash flow from operating activities: -¥1.07 billion (outflow), compared to -¥166 million last year.

• Total assets at period end: ¥33.55 billion, up 3.39% from year-end 2023.

Outlook and guidance

• Company expects continued industry challenges from centralized procurement, price controls, and payment reforms, but sees opportunities in supply chain services and digital transformation.

• Will focus on core business, innovation, compliance, and risk management to drive high-quality growth.